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Characterization of a G1P[8] rotavirus causing an
outbreak of gastroenteritis in the Northern Territory,
Australia, in the vaccine era
Celeste M Donato1,2, Daniel Cowley1, Thomas L Snelling3,*, Asmik Akopov4, Ewen F Kirkness4
and Carl D Kirkwood1,2
In 2010, a large outbreak of rotavirus gastroenteritis occurred in the Alice Springs region of the Northern Territory, Australia. The
outbreak occurred 43 months after the introduction of the G1P[8] rotavirus vaccine RotarixH. Forty-three infants were hospitalized
during the outbreak and analysis of fecal samples from each infant revealed a G1P[8] rotavirus strain. The outbreak strain was adapted
to cell culture and neutralization assays were performed using VP7 and VP4 neutralizing monoclonal antibodies. The outbreak strain
exhibited a distinct neutralization resistance pattern compared to the RotarixH vaccine strain. Whole genome sequencing of the 2010
outbreak virus strain demonstrated numerous amino acid differences compared to the RotarixH vaccine strain in the characterized
neutralization epitopes of the VP7 and VP4 proteins. Phylogenetic analysis of the outbreak strain revealed a close genetic relationship
to global strains, in particular RVA/Human-wt/BEL/BE0098/2009/G1P[8] and RVA/Human-wt/BEL/BE00038/2008/G1P[8] for
numerous genes. The 2010 outbreak strain was likely introduced from a globally circulating population of strains rather than evolving
from an endemic Australian strain. The outbreak strain possessed antigenic differences in the VP7 and VP4 proteins compared to the
RotarixH vaccine strain. The outbreak was associated with moderate vaccine coverage and possibly low vaccine take in the population.
Emerging Microbes and Infections (2014) 3, e47; doi:10.1038/emi.2014.47; published online 2 July 2014
Keywords: Australia; diarrheal outbreak; G1P[8]; full-genome analysis; rotavirus, RotarixH
INTRODUCTION
Rotavirus is the predominant cause of acute gastroenteritis in young
children worldwide.1 A high burden of rotavirus disease is present in
both developing and developed countries resulting in an estimated
453 000 annual deaths, principally in Asia and sub-Saharan Africa.1,2
Rotavirus belongs to the Reoviridae virus family and is a non-
enveloped, icosahedral virus and the 11 segment double-stranded
RNA (dsRNA) genome encodes six structural viral proteins (VP1–4,
VP6, VP7) and six non-structural proteins (NSP1–5/6).3 Rotavirus
strains can be classified into eight groups (groups A–H) based on
the genetic characteristics of the inner capsid protein (VP6); group
A strains are the most common cause of rotavirus disease in humans.4
Rotavirus strains can be further classified based on the two outer
capsid proteins into G (glycoprotein, VP7) and P (protease-sensitive,
VP4) genotypes respectively; these proteins also elicit type-specific and
cross-reactive neutralizing antibody responses.3 A genotyping clas-
sification system based on the open reading frame of each gene has
been adopted; Gx–P[x]–Ix–Rx–Cx–Mx–Ax–Nx–Tx–Ex–Hx.5 To
date, 27 G (VP7), 37 P (VP4), 17 I (VP6), 9 R (VP1), 9 C (VP2),
8 M (VP3), 18 A (NSP1), 10 N (NSP2), 12 T (NSP3), 15 E (NSP4)
and 11 H (NSP5) genotypes have been described.5–9
Two live-oral rotavirus vaccines; RotarixH (GlaxoSmithKline
Vaccines, Rixensart, Belgium) and RotaTeqH (Merck and Co. Inc.,
Whitehouse Station, NJ, USA) have been demonstrated to be effi-
cacious in large clinical trials and are included in vaccination programs
of numerous countries worldwide.10–12 RotarixH and RotaTeqH have
been highly efficacious in decreasing the burden of rotavirus gastro-
enteritis in several countries worldwide including Brazil, Belgium, the
United States, Nicaragua, Austria andMexico.13–17 RotarixH is a live-atte-
nuated monovalent vaccine comprised of a single G1P[8] strain and is
administered in a two-dose schedule at 2 and 4 months of age.18
RotaTeqH is a live-attenuated, pentavalent, human-bovine reassortant vac-
cine administered in a three-dose schedule at 2, 4 and 6 months of age.19
Rotavirus vaccines were introduced into the Australian National
Immunization Program in July 2007. RotarixH was introduced in
the Northern Territory in October 2006 due to the high burden of
rotavirus disease experienced in the region, particularly in Indigenous
infants.20 Vaccine introduction has decreased the burden of rotavirus
disease in several locations around Australia.20 The sole exception is
Central Australia a large region of the Northern Territory encompass-
ing Alice Springs and surrounding communities with a high Indigen-
ous Australian population.21 In Central Australia there has been no
clear decline in rotavirus notification rates despite the introduction of
routine infant vaccination with RotarixH.21,22 Outbreaks of rotavirus
gastroenteritis have continued to occur in Central Australia in the
vaccine era, particularly affecting the town of Alice Springs and
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surrounding communities which place a high demand on health-care
facilities.21
During May and June 2010, a large G1P[8] rotavirus outbreak
occurred in Alice Springs that resulted in a considerable number of
children hospitalized with severe gastroenteritis. The aim of this study
was to perform a genetic and antigenic characterization of the G1P[8]
rotavirus strain responsible for the outbreak. A comparison of the
outbreak strain to other Australian and international G1P[8] strains
was performed to establish its context within the global rotavirus
population.
MATERIALS AND METHODS
Stool specimens
A total of 43 fecal samples were collected from infants (f38months of
age) presenting to hospital with severe gastroenteritis during a rota-
virus outbreak in the Alice Springs region of the Northern Territory
between 10May and 15 June 2010. Patient information including date
of birth, date of sample collection and gender was routinely collected.
The length of hospitalization, immunization status with regard to
the RotarixH rotavirus vaccine was obtained where possible. Fecal sam-
ples were frozen, stored at 2706C and forwarded to the Australian
Rotavirus Reference Centre in Melbourne, Victoria. G1P[8] samples
collected in 2010 were analyzed from Darwin (n520), Gove (n512),
Katherine (n526), Tennant Creek (n516) and remote regions of the
Northern Territory and Western Australia (n528). Additional G1P[8]
samples circulating in neighbouring states South Australia (n57),
Queensland (n52) and Western Australia (n55) in 2010 were also
analyzed.
Nucleic acid extraction
Rotavirus dsRNAwas extracted from clarified 20% (w/v) fecal suspen-
sions using a RNA extraction kit (QIAampH Viral RNAmini kit (spin
protocol), Qiagen, Inc., Hilden, Germany) in accordance with the
manufacturer’s instructions.
Polyacrylamide gel electrophoresis
The 11 segments of dsRNA were separated on 10% (w/v) polyacryla-
mide gel with 3% (w/v) polyacrylamide stacking gel at 25 mA for 16 h.
The genome migration patterns (electropherotypes) were visualized
by silver staining according to the established protocol.23,24
Viruses and adaptation of strains to MA104 culture
The 2010 G1P[8] outbreak strain was adapted to culture in MA104
cells. Filtered 20% (w/v) fecal extracts were activated with 10 mg/mL
porcine trypsin (Sigma, St Louis, MO, USA) at 376C for 30 min and
inoculated onto 2.53106 MA104 cells in DMEM supplemented with
1 mg/mL porcine trypsin (Sigma). Cultures were incubated at 376C
with 5% CO2 and maintained in suspension culture using a rotary
mixer. At 24 h post inoculation, an additional 13106 MA104 cells
were added to the suspension culture. At 96 h post inoculation, the
virus was released by three cycles of freeze–thaw at2806C and clarified
by centrifugation at 4000g for 10 min. The viruses underwent serial
passage in suspension for six passages and were adapted to stationary
phase by three passages in MA104 cells. The electropherotypes of the
adapted strains were compared to the pattern derived from the ori-
ginal stool sample. The VP7 and VP4 genes of the adapted virus was
sequenced as previously described to ensure conservation of protein
sequence following adaptation.25 Virus titer was monitored during
passage using indirect immunofluorescence in MA104 cells.26 The
standard human rotavirus strains RV4 (G1P[8]), F45 (G9P[8]) and
D (G1P[8]), as well as RotarixH, were propagated inMA104 cells in the
presence of trypsin.
Neutralization of strains with monoclonal antibody and polyclonal
antisera
Adapted 2010 G1P[8] outbreak virus and control viruses were studied
in a fluorescent focus reduction neutralization assay with neutralizing
monoclonal antibodies (N-MAbs) and polyclonal sera, as described
previously.26 Four rotavirusN-MAbs RV4:1, RV4:2, RV4:3 andRV4:5,
reactive with the VP7 antigen of human G1P[8] rotavirus RV4, were
used.27 The VP4-specific N-MAb F45:4 reactive to P[8] antigen of F45
was also used.28,29 Rabbit hyperimmune antisera raised to RV4 was
also used.27 The criteria for resistance to neutralization was defined as
a reduction in neutralization titer of at least 1 log, when compared to
the homologous virus titer.
Amplification and nucleotide sequencing of the rotavirus genome
segments
The extracted dsRNAs of five representative G1P[8] 2010 outbreak
samples were sent to the J Craig Venter Institute (Rockville,MD,USA)
for high-throughput reverse transcription-polymerase chain reaction
and Sanger sequencing as previously described.30 Briefly, reverse tran-
scription-polymerase chain reaction primers were designed at 600 bp
intervals along the sense and antisense RNA strand of each gene
to ensure high coverage by reverse transcription-polymerase chain
reaction.
Phylogenetic analysis
Nucleotide similarity searches were conducted using the Basic Local
Alignment Search Tool server on the GenBank database at the
National Center for Biotechnology Information, Bethesda, MD,
USA (http://www.ncbi.nlm.nih.gov). The nucleotide (nt) and
deduced amino acid (aa) sequences of each gene were compared with
sequences available in the GenBank database that possessed the entire
open reading frame and multiple alignments constructed using the
MUSCLE algorithm in the MEGA5.20 program.31,32 The optimal
evolutionary model was selected for each gene based upon the
Akaike information criterion (corrected) ranking implemented in
jModelTest.33,34 Maximum likelihood phylogenetic trees using the
models of nucleotide substitution GTR1I1GG4 (VP1, VP2, VP3,
NSP1 and NSP3), GTR1GG4 (VP4 and VP6), TrN1GG4 (VP7,
NSP2 and NSP4) and HKY1GG4 (NSP5) were generated using
MEGA5.20.31 The robustness of branches was assessed by bootstrap
analysis with 1000 pseudoreplicate runs. Nucleotide and amino acid
distance matrixes were calculated using the P-distance algorithm in
MEGA5.20.31 Structural analysis of the VP7 protein (PDB ID: 3FMG)
was performed using PyMOL.35
Assignment of genotypes
The genotypes of each of the 11 genome segments of the 2010 G1P[8]
outbreak strains were determined using the online rotavirus genotyp-
ing tool RotaC v2.0 (http://rotac.regatools.be).36
Accession numbers
The nucleotide sequences for genes described in this study have been
deposited in GenBank under the accession numbers RVA/Human-wt/
AUS/CK00096/2010/G1P[8] (JX027934–JX027944), RVA/Human-wt/
AUS/CK00097/2010/G1P[8] (JX027945–JX027955), RVA/Human-wt/
AUS/CK00099/2010/G1P[8] (JX027956–JX027966) and RVA/Human-
wt/AUS/CK00100/2010/G1P[8] (JX027967–JX027977). For simplicity,
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the strains will be referred to by their common name CK00096,
CK00097, CK00098, CK00099 and CK00100.
RESULTS
Sample characterization
G1P[8] (n543) samples were collected from patients hospitalized
with severe gastroenteritis during the 2010 Alice Springs rotavirus
outbreak. The average age of infants was 5.9 months (1–38 months),
and 53.3% of patients were male. Based on age, 42/43 infants were
eligible to be vaccinated with at least the primary dose of RotarixH. A
single patient was too young to be vaccinated. Vaccination status was
available for 29 patients, seven patients had received the first dose of
RotarixH and ten patients had received both doses. Five patients did
not receive the second dose despite being eligible. Seven patients had
not been vaccinated despite being of an eligible age. The remaining 13
patients had no vaccination history recorded and were assumed to not
have been vaccinated.
Polyacrylamide gel electrophoresis
All Alice Springs samples analyzed during the outbreak had an identical
electropherotype and strains possessing the outbreak electropherotype
circulated in the region until mid-August, 2010. Strains analyzed from
other regions of the Northern Territory (excluding Gove) and remote
Western Australia exclusively possessed the outbreak electrotype
detected between May and July 2010. The outbreak electropherotype
was also observed in a single South Australian, a single Queensland
and three Western Australian samples circulating in June/July 2010.
Neutralization of 2010 G1P[8] outbreak samples
Fluorescent focus reduction neutralization assay was used to identify
potential antigenic differences between a culture adapted isolate
(V474) from the 2010 G1P[8] outbreak, RotarixH and control viruses.
A panel of VP7 N-MAbs and polyclonal sera derived against RV4
(G1P[8]) and N-MAb derived to VP4 of F45 (G9P[8]) were used to
determine neutralization profiles (Table 1). The 2010 G1P[8] outbreak
virus was neutralized with the N-MAbs RV4:1, RV4:2, F45:4; however,
it was resistant to neutralization by the VP7 MAbs RV4:3 and RV4:5,
and rabbit anti-RV4 sera. In contrast, RotarixH was neutralized by the
VP7 N-MAbs RV4:1, RV4:2, RV4:3, RV4:5 and the rabbit RV4 poly-
clonal sera, but was resistant to neutralization by the VP4 N-MAb
F45:4. The distinct neutralization patterns of the 2010 G1P[8] outbreak
virus and RotarixH demonstrate differences in the antigenic profile of
these viruses, suggesting alterations in VP7 and VP4 proteins.
Comparison of the Alice Springs 2010 G1P[8] outbreak strain to
RotarixH vaccine VP7 and VP4 genes
The VP7 gene of the 2010 outbreak samples possessed 94.2% nt
and 95.7% aa identity the VP7 gene of RotarixH. The amino acid
differences between the outbreak strains and RotarixH were analyzed
and mapped to the VP7 trimer (Figure 1), identifying several changes
in regions of biological function (Figure 2). Several changes in the VP7
protein were located within antigenic regions, T91N and N94S in
antigenic region A and M217T in antigenic region C. An additional
change was identified at position K291R previously identified in neut-
ralization escape mutants.27 The N94S change identified in the out-
break virus correlated with the loss of neutralization by N-MAb RV4:3
and RV4 polyclonal sera.27 Similarly, the outbreak virus was resistant
to neutralization with RV4:5 when compared to RotarixH. The N-
MAb RV4:5 requires the sequence asparagine-lysine at position 147–
148 in antigenic region B for neutralization, plus additional uniden-
tified amino acids.27 Resistance to RV4:5 by strain D correlates with
theN147S change in antigenic region B (Figure 2). The outbreak strain
is resistant to RV4:5, despite a conserved amino acid sequence in
antigenic region Bwhen compared to RV4 and RotarixH. This suggests
that additional surface exposed amino acids, potentially the S123N
change, are responsible neutralization resistance.
The VP4 genes of the 2010 outbreak samples possessed 90.2%–
90.3% nt and 94.5%–94.6% aa identity to the RotarixH vaccine strain.
The VP4 protein undoes proteolytic cleavage by trypsin into two sub-
units; VP8* (aa 1–247) and VP5* (aa 248–776) which enhances viral
infectivity.3 The Y385D change that differentiated RotarixH and the
outbreak virus was identified within the hydrophobic apex of VP5*, a
conformationally dependent antigenic region.37,38 The change at posi-
tion 385 correlates with neutralization resistance of RotarixH with N-
MAb F45:4, which selects neutralization escape mutants at position
392 within this antigenic region of VP5*.29
Whole genome analysis of the Alice Springs 2010 G1P[8] outbreak
samples
Five representative strains collected during the outbreak were selected
for whole genome sequence analysis and possessed the archetypal Wa-
like genome constellation G1-P[8]–I1–R1–C1–M1–A1–N1–T1–E1–
H1. A high-quality sequence read could not be achieved for
CK00098 and the genome was not included in the phylogenetic ana-
lysis. CK00096, CK00097, CK00099 and CK00100 shared 100% nt and
aa identity for all genes except, NSP1 (99.9% nt and 99.8% aa), NSP2
and VP4 (99.9% nt and 99.7% aa).
Phylogenetic analysis of the Alice Springs 2010 G1P[8] outbreak
samples
Phylogenetic analysis of each of the 11 gene segments was conducted
to investigate the genetic relationship of the outbreak strain to
Table 1 Fluorescent focus reduction neutralization assay
Strain RV4:1 RV4:2 RV4:3 RV4:5 F45:4 RV4 (poly)
RV4 720000 125000 210 000 125000 12 000 78000
D 41000 3783 330 000 ,100 ND 59000
F45 ND ND ND ND 1800 ND
V474 137000 29333 ,100 327 30 000 230
ROTARIX 295 000 4867 203 667 2417 593 40667
Abbreviation: ND, not done.
Neutralization titers are reported as the reciprocal dilution, which results in a 50%
fluorescent focus reduction. Titers are representative of three independent assays.
201
217
268
123
91
94
291
Figure 1 A surface representation of the VP7 trimer (PDB ID: 3FMG). Each
trimer is colored a different shade of gray and the antigenic regions A, C and F
are colored light blue, dark blue andmid blue, respectively. The surface exposed
amino acid residues that differ between the 2010 G1P[8] Alice Springs outbreak
strain and RotarixH vaccine strain are shown in red.
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Australian and global strains. In each tree, the 2010 G1P[8] outbreak
strains clustered within large, diverse clades that were comprised of
contemporary global isolates (Supplementary Figures S1, S2 and S3).
The VP7 gene of the outbreak strain shared the highest genetic iden-
tity (99.9% nt and 99.7% aa) to numerous strains circulating in Asia
between 2004 and 2010 and RVA/Human-wt/BEL/BE00098/2009/
G1P[8]. The outbreak strains shared the highest genetic similarity to
RVA/Human-wt/BEL/BE00098/2009/G1P[8] for the VP4 (99.7% nt
and aa), VP2 (99.9% nt and aa), VP6 (99.7% nt and 100% aa), NSP1
(99.7% nt and 99.8% aa) and NSP3 (99.9% nt and 100% aa) genes.
The outbreak strain shared the highest genetic similarity to RVA/
Human-wt/BEL/BE00038/2008/G1P[8] for VP1 (99.8% nt and 99.9%
aa) and VP3 (99.8% nt and 99.8% aa). The NSP2 gene shared 99.7%
nt and aa similarity to RVA/Human-wt/BEL/BE00098/2009/G1P[8],
RVA/Human-wt/USA/VU-06-07-21/2006/G3P[8] and RVA/Human-
wt/USA/2007719674/2007/G1P[8], while the NSP4 gene shared 99.6%
nt and 100% aa similarity to RVA/Human-wt/USA/VU-08-09-24/2008/
G3P[8], RVA/Human-wt/USA/2007719674/2007/G1P[8] and RVA/Human-
wt/RUS/Nov08-3281/2008/G3P[8]. The NSP5 gene shared 99.8% nt
and 99.5% aa similarity to RVA/Human-wt/THA/CU875-BK/2010/
G1P[8], RVA/Human-wt/USA/2009726997/2009/G3P[8] and RVA/
Human-wt/USA/VU08-09-7/2008/G3P[8].
DISCUSSION
The inclusion of rotavirus vaccines onto the Australian National
Immunization Program has decreased rotavirus associated hospitali-
zations, emergency room visits and episodes of gastroenteritis in sev-
eral regions.20 In contrast, vaccination has not been associated with
decreased rotavirus notifications in Central Australia; a large region of
the Northern Territory encompassing Alice Springs and surrounding
communities with a high Indigenous Australian population.21 We
report the characterization of a G1P[8] rotavirus outbreak that
occurred in Alice Springs between May and June 2010, which resulted
in the hospitalization of 43 patients. This is the first G1P[8] outbreak
in theNorthern Territory following the introduction of the homotypic
RotarixH vaccine. Electropherotype and sequence analysis identified
that a single G1P[8] strain was responsible for the outbreak. The strain
was also observed to be circulating in high numbers in other regions of
the Northern Territory (Darwin, Katherine and Tennant Creek); 500–
1500 km from Alice Springs. The 2010 G1P[8] outbreak strain was
also circulating in low numbers in Queensland, South Australia and
Western Australia in the months following the outbreak. However,
routine surveillance in the 2010–2011 period revealed that G1P[8]
strains accounted for 26.5% of strains identified Australia-wide and
no state (regardless of vaccine used) experienced a significant detec-
tion of G1P[8] strains except the Northern Territory, due to the con-
tinued circulation of the outbreak strain in the region.39
Both the VP7 and VP4 proteins are involved in eliciting protective
immunity and the production of neutralizing antibodies.3 Antigenic
differences were identified between the outbreak G1P[8] strain and
RotarixH in both VP7 and VP4 using N-MAbs, correlating with amino
acid changes in known neutralization epitopes. Similar changes in
antigenic regions of VP7 and VP4 have been previously reported in
other contemporary G1P[8] strains circulating in Belgium and glob-
ally.40 Most neutralizing antibodies to the parental strain of RotarixH
(89-12) are to the VP4 protein; five VP4 amino acid changes (G51D,
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Figure 2 Alignment of VP7 gene of the prototype G1P[8] strains RV4, D, the 2010 G1P[8] Alice Springs outbreak strain and RotarixH vaccine strain. Amino acid
differences between these strains are shaded. Residues comprising the antigenic regions are defined within in brackets. The sites shown to escape neutralization with
monoclonal antibodies include RV4:1 (sites 147 and 148, filled circle), RV4:2 (sites 213, filled square), RV4:3 (site 94, filled triangle) and RV4:5: (sites 147, 148 and
other undefined sites, filled right pointing triangle).
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L167F, S331F, D385Y and N695I) identified during vaccine attenu-
ation are thought to significantly reduce serum neutralization titers
following RotarixH vaccination when compared to infection with the
parental 89-12 strain.41 One VP4 amino acid change identified during
89-12 attenuation is D385Y, a site selected in neutralization escape
mutants of the human rotavirus KU (G1P[8]).41,42 The Y385D change
which differentiates RotarixH and the outbreak G1P[8] strain suggests
similar antigenic changes in VP4 as a potential mechanism for neut-
ralization escape. However, preliminary data using sera from children
who seroconverted to RotarixH indicate that it is able to neutralize the
G1P[8] outbreak strain (unpublished observations). In addition, mul-
tiple other viral antigens including VP2, VP6, NSP2 and NSP4 are
thought to be important in rotavirus immunity.43
Phylogenetic analysis of the 2010 outbreak samples identified the
strain was similar to globally circulating G1P[8] strains, forming large
diverse clusters with contemporary G1P[8] strains isolated from numer-
ous countries. The outbreak strain shared the highest degree of genetic
identity to G1P[8] strains circulating in Belgium in 2008 and 2009 for
several genes. Individual genes also shared a high degree of genetic
identity to G3P[8] strains isolated in America (2006–2009), Russia
(2008) and a G1P[8] strain isolated in Thailand in 2010. Interestingly,
the VP7 gene shared the highest genetic relatedness to a widely circulat-
ing gene identified in Hong Kong, Japan and China between 2004, 2006–
2008 and 2010, as well as Belgium. The finding that the 2010 G1P[8]
outbreak strain shared a higher degree of genetic relatedness to global
strains than to previously characterized Australian G1P[8] strains sug-
gests that this strain was recently introduced from a global population
rather than evolving from an endemic Australian strain.
RotarixH vaccine effectiveness (VE) has varied in Alice Springs during
previous rotavirus outbreaks. During the 2009 G9P[8] outbreak, VE for
two doses against all hospitalizations for gastroenteritis was 77.7% (95%
confidence interval, 40.2%–91.7%).44 A lower two-dose VE of 19%
(95% confidence interval: 2105%–68%) was observed during a 2009
G2P[4] outbreak.45 While the VE in the current outbreak has not been
determined, the identification of a homotypic G1P[8] strain among
fully vaccinated individuals suggests a possibly reduced VE in this per-
iod. In 2010, the reported two-dose RotarixH vaccine coverage in the
Northern Territory was 78.4%, considerably lower than other
Australian states (83.2%–88.0%), with only 71.1% of Indigenous
infants vaccinated compared to 85.1% of non-Indigenous infants.21,46
Vaccine coverage of children hospitalized with rotavirus gastroenteritis
during the outbreak was low, with 50% of eligible infants vaccinated.
The overall efficacy of RotarixH has been lower in South Africa and
Malawi compared to European and Latin American studies, correl-
ating with lower anti-rotavirus seroconversion and IgA titer following
vaccination.47,48 In addition, the homotypic and heterotypic immun-
ity acquired following natural rotavirus infections is less in settings
with a high disease burden and other comorbidities.49 Several factors
have been implicated in lower natural immunity and VE in these
settings, including host characteristics such as poor nutritional status,
underlying environmental enteropathy, and high maternal anti-rota-
virus antibodies which might neutralize vaccine viruses. Among
Indigenous infants in the Northern Territory, the burden of diarrheal
disease is high, with admissions coded for enteric infections occurring
at a rate 10-fold higher than among non-Indigenous infants.50 It is
possible that comorbidities present in theNorthern Territory Indigen-
ous population contributes to reduced immunological response fol-
lowing RotarixH vaccination. Assessing rotavirus sera responses and
IgA titer following vaccination may provide important insights into
the effectiveness of RotarixH in this population.
In conclusion, we characterized a G1P[8] rotavirus outbreak in
Central Australia in the vaccine era. TheG1P[8] outbreak strain exhib-
ited high genetic relatedness to contemporary global strains and exhib-
ited antigenic differences to the VP4 and VP7 proteins of RotarixH.
The outbreak was more likely the result of one or more factors includ-
ing suboptimal vaccine uptake, low primary immune responses or
waning immunity in this population rather than the circulation of a
strain associated with increased pathogenicity or vaccine escape. This
study emphasizes the need for continued surveillance of rotavirus
strains to help guide current and future vaccination strategies.
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